These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7639009)

  • 1. A rapid test for measuring the infectivity of Yellow Fever vaccine.
    Sood DK; Aggarwal RK; Kumar S; Sokhey J
    Vaccine; 1995 Apr; 13(5):427-8. PubMed ID: 7639009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The thermal stability of yellow fever vaccines.
    Ishak R; Howard CR
    Mem Inst Oswaldo Cruz; 1990; 85(3):339-45. PubMed ID: 2134708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches for the standardization and validation of a real-time qPCR assay using TaqMan probes for quantification of yellow fever virus on clinical samples with high quality parameters.
    Fernandes-Monteiro AG; Trindade GF; Yamamura AM; Moreira OC; de Paula VS; Duarte AC; Britto C; Lima SM
    Hum Vaccin Immunother; 2015; 11(7):1865-71. PubMed ID: 26011746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus.
    Liprandi F
    J Gen Virol; 1981 Oct; 56(Pt 2):363-70. PubMed ID: 7310380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A W.H.O. collaborative study of in vitro and in vivo methods for the assay of yellow fever vaccines.
    Seagroatt V; Magrath DI
    J Biol Stand; 1983 Jan; 11(1):47-54. PubMed ID: 6833303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study on the stability of 17D-204 yellow fever vaccine before and after stabilization.
    Sood DK; Aggarwal RK; Sharma SB; Sokhey J; Singh H
    Vaccine; 1993; 11(11):1124-8. PubMed ID: 8249431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro potency assay for yellow fever vaccines: comparison of three vero cell lines sources.
    Fournier-Caruana J; Poirier B; Garnier F; Fuchs F
    Biologicals; 2000 Mar; 28(1):33-40. PubMed ID: 10799054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of an end-point microassay for yellow fever vaccine.
    Husson van Vliet J
    Biologicals; 1990 Jan; 18(1):25-7. PubMed ID: 2317350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation in NS5 protein attenuates mouse neurovirulence of yellow fever 17D vaccine virus.
    Xie H; Ryman KD; Campbell GA; Barrett AD
    J Gen Virol; 1998 Aug; 79 ( Pt 8)():1895-9. PubMed ID: 9714237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collaborative study to assess the suitability of a candidate International Standard for yellow fever vaccine.
    Ferguson M; Heath A
    Biologicals; 2004 Dec; 32(4):195-205. PubMed ID: 15572101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
    J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of yellow fever vaccine.
    Monath TP
    Dev Biol Stand; 1996; 87():219-25. PubMed ID: 8854020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yellow fever vaccine: comparison of the neurovirulence of new 17D-204 Stamaril™ seed lots and RK 168-73 strain.
    Moulin JC; Silvano J; Barban V; Riou P; Allain C
    Biologicals; 2013 Jul; 41(4):238-46. PubMed ID: 23763825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An inactivated cell-culture vaccine against yellow fever.
    Monath TP; Fowler E; Johnson CT; Balser J; Morin MJ; Sisti M; Trent DW
    N Engl J Med; 2011 Apr; 364(14):1326-33. PubMed ID: 21470010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of chloroquine prophylaxis on yellow fever vaccine antibody response: comparison of plaque reduction neutralization test and enzyme-linked immunosorbent assay.
    Barry M; Patterson JE; Tirrell S; Cullen MR; Shope RE
    Am J Trop Med Hyg; 1991 Jan; 44(1):79-82. PubMed ID: 1996743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity.
    Freire MS; Mann GF; Marchevsky RS; Yamamura AM; Almeida LF; Jabor AV; Malachias JM; Coutinho ES; Galler R
    Vaccine; 2005 Mar; 23(19):2501-12. PubMed ID: 15752837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability-related studies on 17D yellow fever vaccine.
    Perraut R; Girault G; Moreau JP
    Microbes Infect; 2000 Jan; 2(1):33-8. PubMed ID: 10717538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice.
    Ryman KD; Ledger TN; Campbell GA; Watowich SJ; Barrett AD
    Virology; 1998 Apr; 244(1):59-65. PubMed ID: 9581778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.